Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People who have been diagnosed with ALL (Acute Lymphoblastic Leukaemia)
- People whose ALL has not responded to standard treatment, or has come back after treatment, and for whom other treatment options are not suitable or cannot be waited for
- People who have signs of the disease present in their bone marrow
- People with a general health and activity level rated at 2 or below on a standard medical scale, meaning they are able to care for themselves even if unable to do heavy physical work (confirm with trial site)
- People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements
- People who are expected to live for at least 12 weeks
Who may not be able to join:
- People whose ALL has spread to the central nervous system (brain and spinal cord) and is currently active
- People diagnosed with Burkitt's lymphoma or a specific type of leukaemia crisis linked to chronic myeloid leukaemia (CML)
- People who have previously received a type of treatment that targets the CD19 protein, unless that treatment was blinatumomab
- People who have previously experienced a severe or life-threatening immune reaction (rated Grade 3 or higher) or serious nervous system side effects while receiving blinatumomab
- People who have had an autoimmune disease (where the immune system attacks the body) that has damaged organs or required long-term immune-suppressing medication within the last 2 years
- People with a history of certain heart or brain/nervous system conditions as defined by the trial's medical guidelines (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hosein Kouros-Mehr, MD, PhD, TriArm Inc.
Phone: +86 13641883361
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events [Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.